Preview

Meditsinskiy sovet = Medical Council

Advanced search

Clinical experience of effective use of palliative targeted therapy in a patient with EGFR-negative lung adenocarcinoma

https://doi.org/10.21518/2079-701X-2019-10-142-145

Abstract

The article describes the experience in effective use of the second-generation EGFR II blocker in palliative target therapy of EGFRnegative lung adenocarcinoma. The use of afatinib in the fifth-line palliative therapy of EGFR-negative lung adenocarcinoma allowed us to achieve a significant positive response to therapy in the lungs and improve the patient’s quality of life.

About the Authors

L. M. Kogonia
State Budgetary Healthcare Institution of the Moscow Region «Vladimirsky Moscow Regional Research Clinical Institute».
Russian Federation

Dr. of Sci. (Med.), Professor of Chair for Oncology and Thoracic Surgery, Faculty of Continuing Medical Education, State Budgetary Healthcare Institution of the Moscow Region «Vladimirsky Moscow Regional Research Clinical Institute».



E. V. Markarova
State Budgetary Healthcare Institution of the Moscow Region «Vladimirsky Moscow Regional Research Clinical Institute».
Russian Federation

Dr. of Sci. (Med.), Oncologist of Surgery Department, Diagnostic Center, Professor of Chair for Oncology and Thoracic Surgery, Faculty of Continuing Medical Education, State Budgetary Healthcare Institution of the Moscow Region «Vladimirsky Moscow Regional Research Clinical Institute»: Teaching Assistant of Chair for Oncology and Thoracic Surgery, Faculty of Continuing Medical Education, State Budgetary Healthcare Institution of the Moscow Region «Vladimirsky Moscow Regional Research Clinical Institute».



G. A. Stashuk
State Budgetary Healthcare Institution of the Moscow Region «Vladimirsky Moscow Regional Research Clinical Institute».
Russian Federation

Dr. of Sci. (Med.), Professor of Chair for Radiodiagnosis, Faculty of Continuing Medical Education, State Budgetary Healthcare Institution of the Moscow Region «Vladimirsky Moscow Regional Research Clinical Institute»:. Principal Researcher of Radiology Department, State Budgetary Healthcare Institution of the Moscow Region «М.F. Vladimirsky Moscow Regional Research Clinical Institute».



M. M. Byakhova
State Budgetary Healthcare Institution of the Moscow Region «Vladimirsky Moscow Regional Research Clinical Institute».
Russian Federation

Cand. of Sci. (Med.), Senior Researcher of Anatomic Pathology Department, State Budgetary Healthcare Institution of the Moscow Region «М.F. Vladimirsky Moscow Regional Research Clinical Institute».



M. M. Akhmetov
State Budgetary Healthcare Institution of the Moscow Region «Vladimirsky Moscow Regional Research Clinical Institute».
Russian Federation

Cand. of Sci. (Med.), Professor of Chair for Oncology and Thoracic Surgery, Faculty of Continuing Medical Education, State Budgetary Healthcare Institution of the Moscow Region «М.F. Vladimirsky Moscow Regional Research Clinical Institute».



References

1. de Jong J.S., van Diest P.J. et al. Expression of growth factors, growth-inhibiting factors and their receptors in invasive breast cancer: correlation with proliferation and angiogenesis. Jour Patholog. 1998;184:53-57.

2. Sharma S.V., Bell D.W., Settleman J. EGFR mutation in lung cancer. Nat Rev Cancer. 2007;7:169-81.

3. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther. 1999;82:241-250.

4. World Cancer Report 2014 http://publications. iarc.fr/Non-Series-Publications/World-Cancer- Reports/World-Cancer-Report-2014 (as of October 10, 2016).

5. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2016 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. [Kaprin A.D., Starinsky V.V., Petrova G.V. State of cancer care in Russia, 2016. M.: Herzen Moscow Cancer Research Institute— branch of National Medical Radiology Research Center of the Ministry of Health of RF, 2017.] (In Russ).

6. Когония Л.М., Маркарова Е.В., Сташук Г.А., Бяхова М.М. Улучшение качества жизни пациентки старческого возраста с немелкоклеточным раком легких на фоне проведения таргетной терапии препаратом – блокатором EGFR-мутации второго поколения. Паллиативная медицина и реабилитация. 2018;2:30-33. [Kogonia L.M., Markarova E.V., Stashuk G.A., Byakhova M.M. Improving the quality of life of an elderly patient with non-small cell lung cancer on the background of targeted therapy with a secondgeneration EGFR mutation blocker. Palliativnaya Meditsina i Reabilitatsia. 2018;2:30-33.]

7. Когония Л.М., Маркарова Е.В. Анализ заболеваемости злокачественными новообразованиями в САО и СЗАО. Социальные аспекты здоровья населения. 2012;электронная версия 3(25), 5. [Kogonia L.M., Markarova E.V. Analysis of the incidence of malignant neoplasms in the Northern Administrative District and North-Western Administrative District. Sotsialnye Aspekty Zdoroviya Naseleniya. 2012;electronic version3( 25),5.] (In Russ).


Review

For citations:


Kogonia LM, Markarova EV, Stashuk GA, Byakhova MM, Akhmetov MM. Clinical experience of effective use of palliative targeted therapy in a patient with EGFR-negative lung adenocarcinoma. Meditsinskiy sovet = Medical Council. 2019;(10):142-145. (In Russ.) https://doi.org/10.21518/2079-701X-2019-10-142-145

Views: 602


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)